LTR Pharma Limited (ASX:LTP)

Market Cap	96.26M
Revenue (ttm)	1.51M
Net Income (ttm)	-5.59M
Shares Out	181.61M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,087
Average Volume	553,013
Open	0.5400
Previous Close	0.5300
Day's Range	0.5250 - 0.5800
52-Week Range	0.2700 - 1.6300
Beta	n/a
RSI	42.50
Earnings Date	Nov 25, 2025

About LTR Pharma

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LTP

Financial Performance

In 2025, LTR Pharma's revenue was 1.51 million, an increase of 2978.25% compared to the previous year's 49,002. Losses were -5.59 million, -19.57% less than in 2024.